Hdl Handle:
http://hdl.handle.net/10147/209090
Title:
Pharmacotherapy of gastroparesis.
Authors:
Quigley, E M
Affiliation:
Department of Medicine, National University of Ireland, Clinical Sciences, Building, Cork University Hospital, Cork, Ireland. equigley@ucc.ie
Citation:
Expert Opin Pharmacother. 2000 Jul;1(5):881-7.
Journal:
Expert opinion on pharmacotherapy
Issue Date:
3-Feb-2012
URI:
http://hdl.handle.net/10147/209090
DOI:
10.1517/14656566.1.5.881
PubMed ID:
11249497
Abstract:
The evaluation and management of gastric motor dysfunction continues to represent a significant clinical challenge. The very definition of what constitutes a clinically relevant disturbance of gastric motility remains unclear. The spectrum of gastroparesis extends from those with classical symptoms and severe delay of gastric emptying to those with dyspepsia and a mild delay in emptying rate. Indeed, for many patients with dyspepsia, the role of gastric emptying delay in the pathogenesis of symptoms, remains unclear. Any assessment of the efficacy of any therapeutic class in gastroparesis must be mindful, therefore, of these variations in definition. For those individuals with severe established gastroparesis, therapeutic success often remains elusive and i.v. erythromycin and oral dopamine antagonists, or substituted benzamides, remain the best options for acute severe exacerbations and chronic maintenance therapy, respectively. Alternatives, currently under investigation, include a number of 5-HT4 agonists, macrolides devoid of antibiotic activity, CCK antagonists and gastric electrical stimulation. Other novel approaches include strategies to address some of the regional abnormalities in gastric motor function that have been identified in some patients with dyspepsia.
Language:
eng
MeSH:
Animals; Gastrointestinal Agents/*therapeutic use; Gastroparesis/*drug therapy/physiopathology; Humans
ISSN:
1465-6566 (Print); 1465-6566 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorQuigley, E Men_GB
dc.date.accessioned2012-02-03T15:12:01Z-
dc.date.available2012-02-03T15:12:01Z-
dc.date.issued2012-02-03T15:12:01Z-
dc.identifier.citationExpert Opin Pharmacother. 2000 Jul;1(5):881-7.en_GB
dc.identifier.issn1465-6566 (Print)en_GB
dc.identifier.issn1465-6566 (Linking)en_GB
dc.identifier.pmid11249497en_GB
dc.identifier.doi10.1517/14656566.1.5.881en_GB
dc.identifier.urihttp://hdl.handle.net/10147/209090-
dc.description.abstractThe evaluation and management of gastric motor dysfunction continues to represent a significant clinical challenge. The very definition of what constitutes a clinically relevant disturbance of gastric motility remains unclear. The spectrum of gastroparesis extends from those with classical symptoms and severe delay of gastric emptying to those with dyspepsia and a mild delay in emptying rate. Indeed, for many patients with dyspepsia, the role of gastric emptying delay in the pathogenesis of symptoms, remains unclear. Any assessment of the efficacy of any therapeutic class in gastroparesis must be mindful, therefore, of these variations in definition. For those individuals with severe established gastroparesis, therapeutic success often remains elusive and i.v. erythromycin and oral dopamine antagonists, or substituted benzamides, remain the best options for acute severe exacerbations and chronic maintenance therapy, respectively. Alternatives, currently under investigation, include a number of 5-HT4 agonists, macrolides devoid of antibiotic activity, CCK antagonists and gastric electrical stimulation. Other novel approaches include strategies to address some of the regional abnormalities in gastric motor function that have been identified in some patients with dyspepsia.en_GB
dc.language.isoengen_GB
dc.subject.meshAnimalsen_GB
dc.subject.meshGastrointestinal Agents/*therapeutic useen_GB
dc.subject.meshGastroparesis/*drug therapy/physiopathologyen_GB
dc.subject.meshHumansen_GB
dc.titlePharmacotherapy of gastroparesis.en_GB
dc.contributor.departmentDepartment of Medicine, National University of Ireland, Clinical Sciences, Building, Cork University Hospital, Cork, Ireland. equigley@ucc.ieen_GB
dc.identifier.journalExpert opinion on pharmacotherapyen_GB
dc.description.provinceMunster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.